PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

VOLUME 51, 1995
SUBJECT AND AUTHOR INDEX

PERGAMON

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Founded by MATTHEW J. WAYNER

US Editor-in-Chief
GEORGE F. KOOB
Department of Neuropharmacology, CVN7
The Scripps Research Institute
10666 N. Torrey Pines Road
La Jolla, CA 92037, USA
Fax: (619) 752-1595
E-mail: gkoob@scripps.edu

European Editor-in-Chief
SANDRA E. FILE
Psychopharmacology Research Unit
Guy's Hospital Medical School
P.O. Box 3448
London SE1 9QH, UK
Fax: 44-171-955-4627
E-mail: pbbeuro@umds.ac.uk

Editorial Advisory Board

LIISA AHTEE, Helsinki, Finland
LEMBIT ALLIKMETS, Tartu, Estonia
ROBERT L. BALSTER, Richmond, VA
GIOVANNI BIGGIO, Cagliari, Italy
MIKE BRILEY, Castres, France
ALLAN C. COLLINS, Boulder, CO
DONALD V. COSCINA, Toronto, Ontario, Canada
JACQUELINE N. CRAWLEY, Bethesda, MD
ANNETTE DOMENEY, Geneva, Switzerland
ADRIAN J. DUNN, Shreveport, LA
BURR EICHELMAN, Philadelphia, PA
WILLIAM J. FREED, Washington, DC
MANUEL FREIRE-GARABAL, Santiago De Compostela, Spain
RICHARD A. GLENNON, Richmond, VA
F. G. GRAEFF, São Paulo, Brazil
M. R. C. GREENWOOD, Davis, CA
ROLAND R. GRIFFITHS, Baltimore, MD
STEPHEN G. HOLTZMAN, Atlanta, GA
AKIRA HORITA, Seattle, WA
CHRIS E. JOHANSON, Baltimore, MD
HAROLD KALANT, Toronto, Ontario, Canada
G. JEAN KANT, Washington, DC
KATHLEEN M. KANTAK, Boston, MA
CONAN KORNETSKY, Boston, MA
J. DAVID LEANDER, Indianapolis, IN
EMINY H. Y. LEE, Taipei, Taiwan
ALLEN S. LEVINE, Minneapolis, MN
WILLIAM J. McBRIDE, Indianapolis, IN
DONALD E. McMILLAN, Little Rock, AR
JACK H. MENDELSON, Belmont, MA
FATHY S. MESSIHA, Grand Forks, ND
ROBERT D. MYERS, Greenville, NC
JUDITH A. PRATT, Glasgow, UK
JAQUELINE SAGEN, Chicago, IL
ROSARIO SAMANIN, Milan, Italy
HERMAN H. SAMSON, Winston-Salem, NC
PAUL R. SANBERG, Tampa, FL
PHIL J. SKOLNICK, Bethesda, MD
LINDA P. SPEAR, Binghamton, NY
CLARE STANFORD, London, UK
MARIE-HÉLÈNE THIÉBOT, Paris, France
DEREK VAN DER KOOY, Toronto, Ontario, Canada
JEANNE M. WEHNER, Boulder, CO
BRUNO E. WILL, Strasbourg, France
J. C. WINTER, Buffalo, NY
ALICE M. YOUNG, Detroit, MI
IAN S. ZAGON, Hershey, PA

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Managing Editors:

In the US:
Gery Schulteis
E-mail: gerschul@riscsm.scripps.edu

In Europe:
Nick Andrews
E-mail: pbbeuro@umds.ac.uk

Production Editor:
Alayne A. Bakken
E-mail: A.BAKKEN@ELSEVIER.COM

Publishing, Subscription, and Advertising Offices:
Elsevier Science Inc., 660 White Plains Road, Tarrytown, NY 10591-5153, USA, E-mail Address: ESUK.USA@ELSEVIER.COM; and Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, England

Published Monthly

Annual Institutional Subscription Rates (1995): North, Central and South America, US$1580.00, Rest of World £1060.00. Associated Personal Subscription Rates are available on request for those whose institutions are library subscribers. Sterling prices exclude VAT. Non-VAT registered customers in the European Community will be charged the appropriate VAT in addition to the price listed. Prices include postage and insurance and are subject to change without notice.

Pharmacology Biochemistry and Behavior is an official journal of the International Behavioral Neuroscience Society. For information about the society, please contact: Marianne Van Wagner, IBNS Central Office, Division of Life Sciences, The University of Texas at San Antonio, 6900 North Loop 1604 West, San Antonio, TX 78249-0662, USA. E-mail: EDITOFF@LONESTAR.UTSA.EDU; Fax: (210) 691-4510. Members of the International Behavioral Neuroscience Society may order personal subscriptions at a concessional rate; details of this rate are available upon request.

Pergamon

Pharmacology Biochemistry and Behavior, Vol. 51, No. 4, pp. I–VIII, 1995
Copyright © 1995 Elsevier Science Ltd
Printed in the USA. All rights reserved
0091-3057/95 $9.50 + .00

SUBJECT INDEX

Abecarnil, 481
Absence epilepsy, 571
Acetic acid test, 675
Acetylcholine, 739
Actigraph, 509
Activity, 541
Acute dependence, 407
Adaptability, 849
Adenosine A_1 receptors, 133
Adenosine A_2 receptors, 133
Adjuvant, 877
AF64A, 667
AF102B, 623
AF150(S), 667
Aggression, 789
Aggressive behavior, 767
Aging, 541
Aging, memory decline, 557
AIDS, 947
Alcohol drinking, 593
Allopregnanolone, 463
α_2 Adrenoceptors, 789
α-Methyl-p-tyrosine, 159
Alternative model, 675
Alzheimer's disease, 509, 557, 667,
Amantadine, 709
Amineptine, 165
Amitriptyline, 65, 623
Amobarbital, 391
Amodiaquin, 843
Amphetamine, 301, 397, 421, 725
Amphetamine derivatives, 473
Amphibians, 675
Amygdala, 331
Analgesia, 323, 535, 693, 699, 715
Anandamide, 3, 731
Angiotensin antagonist, 593
Angiotensin II, 83, 593
Angiotensin III, 593
Animal model(s), 553, 947
Animal hypnosis, 577
Anorectics, 89
Anti-Parkinsonian drugs, 249
Antagonist, 815
Anticholinergic, 271
Anticholinergic drug, 249
Antidepressant(s), 165, 331, 849
Antidepressant drugs, 565
Antinociception, 655, 855
Antioxidant enzymes, 627
Antipredator defense, 235
Antipsychotic drugs, 565
Anxiety, 199, 211, 235
Anxiogenic drug, 795
Anxiolytics, 391, 635, 849
AP5, 855
Apamin, 843
Apomorphine, 681
Arachidonylethanolamide, 731
Arthropoda, 223
Aspartic acid, 715
Atropine sulphate, 709
Atypical antipsychotic, 561
Aversion, 317, 457
Avoidance, 601

Barbiturates, 391
Barrel rotation, 37
BDB, 473, 477
Behavior, 29, 263, 331, 353, 509
Behavioral depression, 339
Behaviour, 611
Behavioural sensitization, 89
Benzodiazepine(s), 363, 391, 499, 721, 815
Benzodiazepine antagonist, 557
Benzodiazepine inverse agonist, 557
Bestatin, 675
β-Adrenergic receptor, 553
β-Adrenergic receptor subtypes, 339
β-Adrenoceptors, 439
β-Carboline, 795
β-CIT, 953
β-Endorphin, 577
Bicuculline, 363
Body core temperature, 217
Body temperature, 245
Body weight gain, 725
Brain, 57, 331, 593, 731
Brain–gut axis, 139
Brain selenium, 747
Brain stem, 581
Bretazenil, 481
Buspirone, 821
Butyrylcholinesterase, 647

C57BL/6J mice, 827
C57BL/6NNia mice, 557
Caffeine, 941
Caffeine deprivation, 941
Calcium ions, 133
Candida albicans, 877
Cannabinoid, 731
Cannabinoid receptors, 731
Cannabinoid receptor agonists, 3
Carassius, 885
Carbamates, 443
Carbamazepine, 391
Cardiac, 509
Carotid bodies, 133
Catalepsy, 175
Catecholamines, 789
Cathinone, 473
Cell mediated, 947
Central amygdala, 759
Central- and peripheral benzodiazepine receptors, 529
Cerebellum, 37, 139
Cerebrospinal fluid, 139
c-fos, 331
CGS 8216, 499
CGS 9896, 499
CGS 21680, 133
Challenge, 789
ChAT, 935
Chemoreceptors, 125
Chickens, 477, 795
Chlordiazepoxide, 391, 481
Chlorisondamine, 693
Cholecystokinin octapeptide, 9
Cholinergic, 369
Cholinergic deficit, 917
Cholinergic system, 279
Cholinesterase, 443
Cholinesterase inhibitor, 415
Chronic administration, 435
Chronic treatment, 77, 175, 635
Cinanserin, 313
Circadian, 947
Circadian rhythm, 541
Clonidine, 69, 263
Clozapine, 561
CNQX, 855
CNS stimulants, 69
Cocaethylene, 285, 549
Cocaine, 285, 313, 379, 521, 549, 661, 687, 705, 759, 781, 827, 901, 953
Cocaine abuse, 661
Cocaine analogues, 953
Cocaine sensitization, 799
Cognitive deficits, 667
Cold exposure, 217, 775
Colonic temperature, 83
Color and position discrimination, 301
Conditioned avoidance responses, 279
Conditioned defecation, 89
Conditioned fear, 407
Conditioned fear stress, 515
Conditioned locomotion, 89
Conditioned place prefences, 89, 549
Conditioning, 331
Conflict behavior, 391, 635
Control of respiration, 133
Convulsion, 309, 363
Convulsive threshold, 363
Copulation, 439
Cortical catecholamines, 861
Corticosterone, 65, 789
Cortisone, 877
CPP, 345

Crab, 223
CRF, 885
Cross-tolerance, 891
Cyclosporine, 877

D_1 agonsit, 617
D_1 dopamine receptor, 767
D_1 receptors, 681
D_2-discriminative stimuli, 77
D_2 partial agonists, 661
D_2 receptors, 565, 681
DA and metabolite levels, 29
DALDA, 149
d-amphetamine, 69
Darodipine, 183
Delayed matching-to-sample, 271, 509
Delayed nonmatching-to-sample task, 929
δ-Opioid agonist, 359
Delta opioid receptor, 655
Δ^9-Tetrahydrocannabinol, 731
Dementia of Alzheimer type, 917
Dependence, 469
Depression, 339, 553, 849
Descending pathway, 655
Designer drugs, 473, 477
Desipramine, 331
Development, 153
Developmental course, 199
Diazepam, 65, 189, 391, 923
Diethylpropion, 89
Digiscan, 13
Dihydrexidine, 521, 617, 767
Dihydroxyphenylacetic acid, 397
Dimethylaminorex isomers, 375
Discriminative stimulus, 705
Divided attention, 189
Dog, 421
DOI, 21
Dopamine, 3, 69, 97, 159, 397, 521, 681, 687, 835, 917
Dopamine D_1 receptors, 759
Dopamine D_2 receptors, 843
Dopamine D_3 receptors, 843
Dopamine receptor(s), 291, 545
Dopamine receptor antagonists, 799
Dopamine receptor occupancy, 175
Dopamine transporter, 953
Dopaminergic neuronal plasticity, 861
Dose discrimination, 49
DPDPE, 57, 655
Drinking, 83
Drug abuse, 375
Drug dependence, 435
Drug discrimination, 69, 379, 491, 561, 661, 759, 953
Drug discrimination study, 375
Dynorphin, 387

ECS, 565
Ecstasy, 301
EEG power spectra, 611
EEG spectral analysis, 353
8-OH-DPAT, 235
Electroconvulsive shock, 565
Emergence test, 297
Emotionality ratings, 199
Endogenous antioxidant system, 581
Enkephalin, 675
Environmental enrichment, 397
Epibatidine, 693
Epilepsy model, 37
Epinephrine, 217, 255
Escape, 601
Escape-deficit, 339
Estradiol, 279
Estrogen, 807
Estrous cycle, 279
Ethanol, 189, 223, 285, 525, 549, 835, 891
Ethologic analysis, 331
Etorphine, 535
Excitatory amino acid antagonists, 855
Excitatory amino acids, 205
Excitotoxic lesions, 739
Exercise, 627, 725
Exploratory activity, 205
Eye control, 37

F-344 rats, 775
Fasting, 885
Fear, 235, 297, 331, 795
Feeding, 641
Feeding test, 499
Fenfluramine, 313, 641
Fentanyl, 535
FG lesion, 935
5-HT and metabolites levels, 29
5-HT_{1A} agonists, 235
5-HT_2 antagonist, 353
5-HT_{2A} antagonist, 235
5-HT_{1A} receptor(s), 211,317, 439
5-HT_2 receptors, 317
5-HT_3 receptor, 835
5-HTP, 21
5-Hydroxytryptamine, 9
5-Hydroxytryptophan, 9
Fixed-ratio discrimination learning, 861, 869
Fixed interval, 481
Flight, 235
Flumazenil, 557, 815
Flurazepam, 909
Food anticipation, 541
Food deprivation, 499
Food intake, 449, 725
Food palatability, 499
Food reinforcement, 301
Foot-shock, 515
Footshock, 407
Forced swimming test, 849
Formalin pain, 577
Fos protein, 175
4-Aminopyridine, 843
4-Methylaminorex analogues, 375
Freezing behavior, 515
Fura2/AM, 57

GABA, 463, 795
GABA receptors, 529
$GABA_A$, 655
$GABA_A$ receptor, 721, 909
$GABA_B$, 655
Gender differences, 601
Gepirone, 235
Glucose, 885
Glutathione, 627
Glutathione peroxidase, 747
Goldfish, 885

[^{3}H]MK-801, 435
Habituation, 223
Hallucinogen, 301
Haloperidol, 175, 291, 601, 709, 843
Head twitches, 183
Head shakes, 21
Heart mitochondria, 627
Heroin, 491, 655
Hippocampal plasticity, 869
Histamine H_1-, H_2-, and H_3-receptors, 923
Histamine receptor, 65
Holeboard maze, 917
Horizontal movement, 359
HS mice, 521
Human, 323, 509, 815, 941
Human studies, 189
Humoral, 947
Huperzine A, 415
Hyperactivity, 13, 159
Hyperphagia, 923
Hypnotics, 571
Hyponeophagia, 199
Hypothermia, 525, 891
Hypoxia, 245

Ibogaine, 103
ICS 205-930, 69, 835
Idazoxan, 69
Immediate early gene, 331
Immunity, 947
Immunization, 877
In vivo microdialysis, 515
Infection, 877, 947
Inferior colliculus, 317
Ingestion, 505
Ingestive behavior, 9
Initial subsensitivity, 391
Intracellular calcium, 57
Intracerebroventricular, 593
Intracranial self-administration, 49
Intrathecal, 855
Intravenous self-administration, 827
IO intake, 9
Ipsapirone, 217
Isolation distress, 463
Isoproterenol, 83
Isradipine, 183

Kainic acid, 205
κ-Opioid agonists, 611
Ketamine, 291
Ketanserin, 69
Kynureninase, 753
Kynurenine aminotransferase, 753
Kynurenines, 753

Lateral hypothalamus, 49
Lateral ventricle, 593
LCGU, 935
L-Deprenyl, 421
Learned helplessness, 553
Learning, 13, 301, 509, 541
Learning and memory, 223
Learning deficits, 917
Lethality, 249, 521, 781
Leukemia, 947
Leukocytes, 339
Levamisole, 877
Light, 947
Limbic, 331
Linear locomotion, 149
Linopirdine, 111
Locomotor activity, 149, 291, 359, 457, 693, 827, 891, 901
Long-sleep, 525
Lorazepam, 189, 721
LS mice, 891

Macaque monkey, 617
Male/female rats, 807
Male rat(s), 9, 439, 545
Marmosets, 443
Maternal separation, 463
MCI-225, 935
MDMA, 301
Mean platelet volume, 217
Mecamylamine, 415, 693
Medial preoptic area (MPOA), 681
Medial prefrontal cortex, 515
Memory, 509, 739
Meperidine, 535
MEPQ, 647
Mesocorticolimbic dopamine system, 491
Metabolic mapping, 37
Metergoline, 69
Methadone, 535
Methamphetamine, 97
Methylazoxymethanol, 869
Methylene blue, 133
Methyl naltrexone, 491
Mice, 49, 313, 457, 525, 601, 747, 753, 947
Microdialysis, 97, 835
Microencephaly, 869
Microinjection, 759
Midazolam, 481, 571
MK-801, 13, 133, 291, 345, 429, 635, 781, 901, 909
Moclobemide, 245
Monkey, 301
Monoamine metabolites, 421
Monoamine oxidase A, 421
Monoamine oxidase B, 421
Monoamine reuptake inhibition, 687
Monoamines, 421
Morphine, 49, 57, 103, 469, 491, 505, 699, 715
Morris water escape task, 111
Morris water maze, 429, 667, 747
Motivation, 301
Motor activity, 97, 647
Motor behavior, 429, 617
Mouse, 3, 111, 249, 291, 297
Mouse brain, 529
Mouse's ambulation, 799
MPTP, 581
μ-Opioid peptide agonists, 149
Muscarinic receptor agonists, 119

N^6-Phenylisopropyladenosine (L-PIA), 133
Naloxone, 675, 715
Naltrexone, 535
Natural killer cell activity, 821
Neonatal 6-hydroxydopamine, 861
Neonatal, 159
Neuroactive steroids, 463
Neuroleptic drugs, 565
Neuropeptide Y, 641
Neuropeptides, 705
Neurosteroid, 463
Neurotensin, 891
Neurotoxicity, 387
Neurotransmitters, 917
Nexus, 473
N^G-monomethyl-L-arginine, 309, 457
Nicotine, 509
Nicotinic, 369
Nicotinic acetylcholine receptor, 693
NIK247, 623, 923
Nisoxetine, 69
Nitric oxide, 309
Nitrous oxide, 323, 815
NMDA, 13, 901
NMDA receptor, 133, 909
NMDA receptor complex, 635
N-Methyl-D-aspartate, 249
N-Methyl-D-aspartate antagonists, 249
N-Methyl-D-aspartate receptor(s), 291, 309
N-Methyl-D-aspartic acid, 205
Noncompetitive NMDA antagonists, 561
Noradrenalin, 917
Norepinephrine, 69, 217, 263, 553, 687
N-Propyl-apomorphine, 175
NS-3 (CG3703), 929
Nuclear proteins, 231
Nucleus accumbens, 397, 681, 835
Nucleus basalis magnocellularis, 739

Odor conditioning, 463
1-(m-chlorophenyl)-biguanide, 835
Open field, 429
Open field behavior, 747, 795
Operant behavior, 301, 647
Operant conditioning, 111
Opiate, 387
Opioid peptides, 705
Opioid receptor, 535
Opioid tolerance, 57
Opioids, 379, 491, 699
Organophosphates, 443
Organophosphorus, 647
Ovariectomy, 279
Oxide, 133
Oxotremorine, 279
Oxycodone, 535

PA, 935
Pain, 323, 469, 577
Palatability, 505
Pancreas, 139
Panic, 235
Paralysis, 387
Paraventricular nucleus, 641
Parkinson's disease, 617
Passive avoidance, 297, 647, 667
Passive avoidance response, 623
p-Chlorophenylalanine, 9
pCl-DPDPE, 359
Penile erection, 709
Pentobarbital, 391, 525
Pentylenetetrazol, 153, 363
Performance, 443
Perifornical hypothalamus, 641
Phagocytosis, 821
Phencyclidine, 291, 435
Phentolamine, 255
Phenylethylamine, 421
Phosphorylation, 231
Physostigmine, 415, 739, 929
Pigeons, 271
Pigeon conflict, 211
Pirenperone, 235
Place conditioning, 457
Place preference, 827
Platelet density distribution, 217
Platelet function, 217
Postnatal handling, 199
Posttreatment, 799
Potassium channels, 843
Prazosin, 69, 255, 263
Pregnancy, 753
Prenatal, 721
Pretreatment, 443
Proestrus, 807
Progesterone, 807
Properties, 705
Propoxyphene, 535
Propranolol, 69, 439, 255, 297
Proprioception, 37
Psychomotor stimulants, 89
Psychomotor, 815
Psychostimulant, 901
Pyruvate dehydrogenase complex, 917

Quercetin, 231
Quinelorane, 681
Quinine, 505
Quinolinic acid, 309, 739
Quinoxalines, 153
Quinpirole, 77, 843
Quipazine, 21

Rabbit, 577, 877
Raclopride, 681
Radial-arm maze, 119, 345, 369, 415, 667, 739
Radial arm maze task, 929
Random-ratio schedules, 941
Rat(s), 29, 69, 83, 111, 133, 153, 165, 199, 205, 263, 271, 285, 331, 359, 379, 429, 435, 463, 549, 571, 581, 611, 667, 681, 705, 759, 789, 917, 923, 929
Rat brain, 65, 339
Rat brain areas, 183
Rat strains, 699
Reactivity, 767
Rearing, 149, 359
Rearing conditions, 767
Rebound changes in discriminative states, 77
Rebound effects, 571
Receptor binding, 435
Receptor supersensitivity, 175
Red nucleus lesions, 29
Reference memory, 345, 415, 667, 739
Reinforcement, 827
Repeated acquisition, 509
Resistance, 947
Response timing, 165
Restraint stress, 699
Reward, 457, 505
Rhesus monkey, 953
Risk assessment, 235
RO 15-3505, 557
RU 35 926 (CI-979), 119
Running wheels, 725

S 14506, 211
S 14671, 211
Salbutamol, 69
SAM, 623
Sardinian alcohol-preferring rats, 21
SART stress, 849
Sarthran, 593
SCH 23390, 521, 681, 759, 781, 799
SCH 39166, 69
Schedule-controlled behavior, 481
Schizophrenia, 561
Scopolamine, 271, 345, 415, 739, 929
SDZ 208-911, 661
SDZ 208-912, 661
Secretin, 469
Seizures, 133, 153, 313, 781
Selenium deficiency, 747
Self-administration, 687, 941, 953

Seminal emission, 709
Senktide, 21
Sensitization, 781, 901
Sensory-motor function, 103
Serotonergic system, 183
Serotonin, 69, 183, 235, 687, 313, 301, 515, 641, 807, 835, 917
Serotonin precursor and metabolite, 183
Sertindole, 353
7-Nitroindazole, 133
7-OH-DPAT, 545
Sex differences, 635
Sexual behavior, 439, 529, 545, 681, 709
Short-term memory, 301
Short-sleep, 525
Simultaneous administration, 799
6-Hydroxydopamine, 159
6-OHDA lesions, 3
Sleep, 877
Sleep apneas, 133
Sleep–wake states, 353, 571
Sodium nitroprusside, 309
Spatial learning, 103
Spatial memory, 429
Spike-wave discharges, 353, 571
Spinal cord, 57, 387
Spinal rat, 855
Spinal transection, 709
Spiperone, 77, 175
Spontaneously hypertensive rats, 869
Squirrel monkeys, 661, 843
SR 141716A, 3
Stereotypy, 149, 359
Stimulus properties of drugs, 285
Stress, 65, 297, 331, 491, 821, 849
Stress-induced analgesia, 675
Striatal and cortical catecholamines, 861
Striatum, 3, 97, 397, 581, 767
Subjective, 323, 815
Sulpiride, 781
Supersensitivity, 535
Swiss–Webster mouse, 235
Switch-off behavior, 317
Symbol digit substitution, 189
Synaptosomes, 57

T-maze, 345
T_3, 885
T_4, 885
Tacrine, 935
Tail flick, 469, 855
Tail skin temperature, 83
Taste, 505
Taste reactivity, 505
TCP, 429
Teleosts, 885
Temperature, 693
Temperature regulation, 255, 263
Temporal memory, 271
Terguride, 661
TH_1, 947
TH_2, 947
THA, 119
Thermal balance, 255
Thiorphan, 675
Third ventricle, 593
Thirst, 593
3α-Hydroxy-5α-pregnan-20-one, 463
3-Bromopyruvate, 917
3,4-Diaminopyridine, 739
3,4-Methylenedioxyphenyl-2-butanamine, 477
Thyroid, 885
Thyroid hormones, 885
Time, 271
Time-course, 285, 635
Time discrimination, 165
Time perception, 301
TimeWand, 509
Tolerance, 363, 469, 481
Toluene, 97
Tonic immobility, 795
Toxicity, 781
Transient amnesia, 119
TRH, 929
Turning, 3
Tyrosine hydroxylase, 775

U50,488H, 57
Ultrasonic vocalizations, 463
Upregulation, 535

Ventral tegmental area, 491
Virus, 947
Vitamin B-6, 753
Volunteer, 323, 815

WAG/Rij strain, 571
Water maze, 103
Wet dog shakes, 21
Withdrawal, 103, 407, 941
Working memory, 119, 271, 345, 415, 557, 667, 739

YM-09151-2, 799
YM796, 623
Yohimbine, 69, 255, 263
Yoked control, 827

Zolpidem, 571
Zucker rat, 255

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 51 1995

AUTHOR INDEX

Abood, L., 369
Abraham, S., 667
Abrahamsen, G. C., 407
Advokat, C., 855
Ahlenius, S., 545
Airaksinen, M. M., 529
Al-Khatib, I., 245
Allen, R. R., 310
Aloisi, A. M., 577
Alonso-Bedate, M., 885
Alonso-Gomez, A. L., 885
Amann, K., 103
Anderson, W. R., 387
Apfelbaum, J. L., 323, 815
Appel, J. B., 65
Arenas, M. C., 601
Aslan, N., 715
Ates, N., 353

Babarczy, E., 469
Balboa, J. L., 821
Banks, W. A., 139
Bannon, A. W., 693
Bardo, M. T., 397
Barrett, J. E., 843
Barrett, R. J., 77
Barzaghi, F., 119
Bass, P. P., 57
Bauer, T., 509
Beck, C. H. M., 331
Bednar, I., 9
Beninger, R. J., 739
Beresford, R. A., 375
Berkman, K., 715
Blanchard, D. C., 235
Blanchard, R. J., 235
Blanchet, G., 429
Blank, K. J., 947
Blengio, M., 69
Boast, C. A., 345
Boegman, R. J., 739
Boulton, A. B., 421
Bowling, S. L., 397
Brão, M. L., 317
Brandeis, R., 667
Brannan, S. K., 553
Broadbent, J., 379
Brocco, M., 211
Bronson, M. E., 473, 477, 481
Brown, C. M., 641
Bryan, S. K., 759
Buckner, E., 635
Burke, T. F., 435
Burkhart-Kasch, B., 827
Busker, R. W., 443
Buxton, S. T., 397
Buzzard, S., 435
Byrne, A., 89

Cain, D. P., 13
Caldarone, B. J., 407
Callahan, P. M., 759
Campbell, A. D., 891
Campi, C. C., 611
Carey, R. J., 901
Carley, D., 125
Carli, G., 577
Carlisle, H. J., 255, 263
Caul, W. F., 77
Cazala, P., 49
Cebeira, M., 731
Chan, K., 535
Cheetham, S. C., 565
Chen, S.-W., 499
Chew, B. H., 37
Ciccocioppo, R., 21
Clark, C. R., 375, 473, 477
Clark, J. T., 439
Clarke, G. D., 611
Clarke, S. N. D. A., 505
Clement, C., 217
Coalson, D., 815
Coenen, A. M. L., 353, 571
Commissaris, R. L., 391, 635
Consolo, S., 29
Coppens, H. J., 175
Corbett, R., 561
Coscina, D. V., 641
Costi, P., 29
Coutts, R. T., 89
Cunningham, C. L., 827
Cunningham, K. A., 759

D'Anci, K., 725
Díaz-Véliz, G., 279
Dai, H., 901
Dall'Olio, R., 183
David, V., 49
Davidson, J. M., 439
Davies, M. F., 499
Davis, B. A., 421
Davis, T., 535
Decker, M. W., 693
Delgado, A. J., 885
De Pedro, N., 885
DePoortere, H., 571
DeRuiter, J., 473, 477
DeSole, M. S., 581
Deutsch, S. I., 133, 909
De Wit, H., 941
Dey, D., 217
Dieckwisch, J., 217
Ding, A., 917
Doctor, B. P., 647
Dokmeci, D., 245
Dokmeci, I., 245
Drinkenburg, W. H. I. M., 571
Drucker, P. C., 463
Dubuc, P. U., 255
Durden, D. A., 421
Dussaubat, N., 279
Duttaroy, A., 535
Dworkin, S. I., 379
Dwoskin, L. P., 397

Egawa, M., 935
Eguchi, J., 935
Erscheid, P. M., 397
Erwin, V. G., 891
Escorihuela, R. M., 199
Esposito, G., 581

Fernández-Rial, J. C., 821
Fernández-Ruiz, J. J., 731
Fernéz-Teruel, A., 199
Ferraz, M., 709
Ferré, P., 199
Ferré, S., 205
Ferretti, C., 69
Fibiger, H. C., 331
File, S. E., 1
Filliat, P., 429
Fisher, A., 667
Flagmeyer, I., 11
Forster, M. J., 557
Françon, D., 571
Frank, S., 627
Frederick, D. L., 310
Fregly, M. J., 83
Freire-Garabal, M., 821
Fresu, L. G., 581
Froelich, L., 917
Fujimoto, J. M., 655
Fukuda, T., 291

Gaggi, R., 183
Gancedo, B., 885
García, E., 199
García, L., 731
Gariépy, J.-L., 767
Gaspard, T. M., 379
Gendreau, P. L., 767
Gessa, G. L., 21
Ghi, P., 65
Gianni, A. M., 183
Gillam, M. P., 310
Giménez-Llort, L., 205
Grahame, M. J., 827
Grella, G., 581
Griebel, G., 235
Groen, B., 443
Gross, P. M., 37
Grupp, L. A., 593
Gunther, K. L., 693

Hafif, N., 667
Haller, J., 789
Harding, S., 593
Hargreaves, E. L., 13
Hasegawa, T., 309
Hata, T., 849
Hatsukami, D., 387
Head, E., 421
Heal, D. J., 565
Hennig, J., 217
Henry, C., 103
Hermans, I., 165
Hill, T. J., 391
Hisanaga, N., 97
Hoffman, B. B., 439
Holtzman, S. G., 699
Hooke, L. P., 387
Hoyer, S., 917
Huang, J., 97
Huffman, E. M., 77
Hull, E. M., 681
Huston, J. P., 901

Ichihara, G., 97
Irifune, M., 291
Ishii, R., 923
Itoh, E., 849
Ivy, G. O., 421
Iwai, A., 623
Iwai, K., 935

Jackson-Smith, P., 103
Jalava, K.-M., 189
Jaspan, J. B., 139
Jhamandas, K., 739
Jiang, W., 473, 477
Johnson, B. J., 617
Jones, C. R. N., 387
Jones, D. J., 553
Jones, J. R., 77
Jung, A., 235

Kameyama, T., 705
Kamijima, M., 97
Kanarek, R. B., 725
Karadag, H. C., 245
Kastin, A. J., 139
Kebabian, J., 953
Kesner, R. P., 103
Kimura, K., 929
Klafta, J., 815
Kleinrok, Z., 29
Kleinsorge, R. J., 391
Koetzner, L., 133, 909
Koff, J. M., 721
Kolasa, K., 29
Kolta, M. G., 525
Komatsu, T., 935
Kondo, H., 97

Koob, G. F., 1
Korf, J., 175
Kovera, C., 509
Kramer, G. L., 553
Krost, M., 901
Kubová, H., 153
Kueny, T., 439
Kuribara, H., 799

LaForge, R. R., 345
Lal, H., 557
Langley, L. K., 509
Larochelle, J. S., 775
Larsson, K., 545
Laschefski, U., 217
Lee, N. M., 387
Lefebvre De Ladonchamps, B., 211
Le Fur, G., 3
Lejeune, H., 165
Levin, E. D., 369
Lewis, M. H., 767
Lichtor, J. L., 815
Lindqvist, E., 159
Loew, G. H., 499
Loucks, J. A., 681
Loupe, P. S., 861, 869
Lukacs, L. G., 909
Luthman, J., 159

Mackevicius, A. S., 953
Mailman, R. B., 767
Maldonado, H., 223
Mallet, P. E., 739
Mareš, P., 153
Marks-Kaufman, R., 725
Marley, R. J., 781
Martin, K. F., 565
Martínez, E., 205
Martin-Iverson, M. T., 89
Massi, M., 21
Mastropaolo, J., 133, 909
Masuda, C. K., 235
Maswood, S., 807
Matsumoto, M., 515
Mattila, M. J., 189
Matuszewich, L., 681
Maurer, S. A., 345
McBride, C., 835
McCarten, J. R., 509
McDonough, J. H., JR., 249
McEachron, D. L., 947
McFalls, E., 509
McLaurin, B. I., 149, 359
McMiller, L. V., Jr., 391
McNaughton, N., 375
Meehan, S. M., 313, 521
Melo, L. L., 317
Meyer, M. E., 149, 359
M'Harzi, M., 111
Miele, E., 581
Miele, M., 581
Migheli, R., 581
Milgram, N. W., 421
Millan, M. J., 211
Miller, A., 553
Miller, L. G., 721
Minamoto, Y., 541
Mitchell, S. H., 941
Mizinga, K. M., 525
Mocaër, E., 165
Monley, J., 509
Monti, D., 125
Mora, S., 279
Mori, E., 705
Moriarty, D. D., 795
Morn, C., 133, 909
Moses, J., 681
Murphy, M. P., 421
Myers, R., 891

Nabeshima, T., 309
Najimi, M., 297
Nakagawa, Y., 929
Nakahara, D., 97
Nakamura, T.-A., 309
Naruse, T., 923
Netter, P., 217
Nishikawa, H., 849
Nomoto, M., 291
Núñez, J. F., 199
Núñez-Iglesias, M. J., 821

Oakes, R. A., 457
Oberler, C., 119
Ogasawara, T., 929
Ogg, B. G., 675
Ögren, S. O., 159
Oktay, Ş., 715
Onat, F., 715
Ono, M., 541
Ono, Y., 97
Opper, C., 217
Oz, N., 667
Ozawa, Y., 623

Palou, A.-M., 119
Panerai, A. E., 577
Panocka, I., 21
Park, C. H., 909
Parker, L. A., 505
Parra, A., 601
Patel, H. R., 557
Patterson, T. H., 323
Paule, M. G., 301
Peacock, V., 617
Pentel, P. R., 387
Petty, F., 553
Pey, G. N., 339
Pey, S. C., 339
Phillips, I., 565
Phillips, T. J., 827
Pirec, V., 323
Poignant, J. C., 165
Poncelet, M., 3
Portaleone, P., 69
Prather, P. L., 557
Prystowsky, M. B., 947
Przypek, J., 725

Quartermain, D., 297
Qureshi, G. A., 9

Radulovacki, M., 125
Rady, J. J., 655
Rägo, L., 529
Ramos, J. A., 731
Reimer, A. R., 89
Ren, X., 339
Rettori, M.-C., 165
Rey-Méndez, M., 821
Richelle, M., 165
Rinaldi-Carmona, M., 3
Risinger, F. O., 457
Romero, J., 731
Roncada, P., 183
Rose, J. E., 369
Rosellini, R. A., 407
Rosenberg, H. C., 363
Rosenzweig-Lipson, S., 843
Rosse, R. B., 133
Rotunda, R., 509
Rowl, N. E., 83
Rowlett, J. K., 397
Ruehl, W. W., 421
Rupani, G., 815
Russell, B. R., 375
Rutherford, D., 855
Rybak, L. P., 627

Saano, V., 529
Sagen, J., 339
Saito, H., 515
Saito, I., 97
Saito, K.-I., 935
Saito, T., 781
Samaan, S. S., 525
Sangha, S., 675
Santi, A., 271
Santos, R., 709
Sapir, M., 667
Saraco, M. G., 223
Satoh, H., 747
Schechter, M. D., 285, 313, 521, 549
Schmierer, D. M., 375
Schneider, J. S., 617
Schreiber, R., 211
Schroeder, S. R., 861, 869
Schutz, A. D., 407
Sebens, J. B., 175
Shah, S., 535
Shaham, Y., 491
Shibata, E., 97
Shibata, S., 541
Shih, T.-M., 249
Shimizu, T., 291
Shimosato, K., 781
Simon, V. M., 601
Sircana, S., 581
Skarsfeldt, T., 353
Smith, E. R., 439
Smolen, A., 753
Södersten, P., 9
Soliman, K. F. A., 525
Somani, S. M., 627
Soubrié, P., 3
Souilhac, J., 3
Spealman, R., 661
Stefanini, E., 21
Stein, E., 667
Stevens, C. W., 675
Stewart, G., 807
Stewart, J., 491
Stino, F. K. R., 525
Stock, H. S., 407
Stock, M. J., 255, 263
Stodgell, C. J., 861
Stoker, D., 439
Stone, E. A., 297
Storch, F. E., 345
Strand, E. J., 77
Suzuki, M., 623
Szabó, G., 469

Takeuchi, Y., 97
Tamura, M., 929
Tang, X. C., 415
Tarssanen, M., 189
Telegdy, G., 469
Tella, S. R., 687
Tessel, R. E., 861, 869
Thapar, P., 323
Tobeña, A., 199
Togashi, H., 515
Toker, F., 715
Toth, L. A., 877
Tumas, K. M., 947
Tümer, N., 775
Tupala, E., 529

Ukai, M., 705
Ukai, Y., 929
Ulugol, A., 245
Uphouse, L., 807
Urichuk, L. J., 89

Vachová, D., 153
Van De Kamp, J. L., 753
van der Staay, F. J., 111
Van Groll, B. J., 57
Van Helden, H. P. M., 443
Van Luijtelaar, E. L. J. M., 353, 571
Vanakoski, J., 189
Velichkova, A. A., 231
Velíšek, L., 153

Wananukul, W., 387
Watanabe, C., 747
Watanabe, S., 541
Watson, H. L., 681
Weaver, D. F., 37
Weed, M. R., 953
Weider, J. M., 463
Weise, L., 271
Welch, S. P., 49
Wesemann, S., 217
Wessinger, W. D., 435
West, W. B., 57
Wilson, A. L., 509
Wirsching, B. A., 739
Wolthuis, O. L., 443
Womer, D. E., 891
Woolfolk, D. R., 699
Woolverton, W. L., 953
Wu, P. H., 421

Xie, Z., 635
Xiong, Z. Q., 415

Yajnik, S., 815
Yamada, K., 309
Yamaguchi, T., 623
Yamamoto, M., 623
Yoburn, B. C., 535
Yoshioja, M., 515
Young, C., 815
Yu, P. H., 421
Yuasa, T., 935

Zacny, J. P., 323, 815, 941
Zangani, D., 581
Zecca, L., 29
Zimmerberg, B., 463